Alterations of PTEN and SMAD4 methylation in diagnosis of breast cancer: implications of methyl II PCR assay

Menha Swellam¹, Entsar A. Saad², Shimaa Sabry²*, Adel Denewer³, Camelia Abdel Malak² and Amr Abouzid³

Abstract

Background: Diagnosis of breast cancer is more complicated due to lack of minimal invasive biomarker with sufficient precision. DNA methylation is a promising marker for cancer diagnosis. In this study, authors evaluated methylation patterns for PTEN and SMAD4 in blood samples using EpiTect Methyl II QPCR assay quantitative PCR technology.

Results: Methylation status for PTEN and SMAD4 were statistically significant as breast cancer patients reported hypermethylation compared to benign and control groups (77.1 ± 17.9 vs. 24.9 ± 4.5 and 15.1 ± 1.4 and 70.1 ± 14.4 vs. 28.2 ± 0.61 and 29.5 ± 3.6, respectively). ROC curve analysis revealed that both PTEN (AUC = 0.992) and SMAD4 (AUC = 0.853) had good discriminative power for differentiating BC from all non-cancer individuals (benign and healthy combined) compared to routine tumor markers CEA (AUC = 0.538) and CA15.3 (AUC = 0.686). High PTEN methylation degree was associated with late stages (84.2 ± 17.4), positive lymph node (84.2 ± 18.5), positive ER (81.3 ± 19.7), positive PgR (79.5 ± 19.1), and positive HER2 (80.7 ± 19.0) vs. 67.4 ± 13.8, 70.6 ± 14.8, 72.8 ± 14.9, 72.5 ± 14.7, and 70.2 ± 13.5 in early stages, negative lymph node, negative ER, negative PgR, and negative HER2, respectively. Similar results were obtained regarding SMAD4 methylation. Sensitivity, specificity, positive and negative predictive values, and accuracy for methylated PTEN were 100%, 95%, 99.1%, 100%, and 95%, respectively when differentiated BC from all-non cancer controls. Interestingly, PTEN could distinguish early BC stages with good sensitivity 84.4%, 51.4%, 69.1%, 72%, and 70%, respectively.

Conclusion: Methylation status of PTEN and SMAD4 is a promising blood marker for early detection of breast cancer. Future studies are needed for their role as prognostic markers.

Keywords: Breast cancer, DNA methylation, Circulating molecular marker, Diagnosis

Background

Breast cancer (BC) is the most widely neoplasm in women [1] that progresses silently, leading to neighboring metastasis and poor prognosis. Moreover classification of breast cancer into relevant molecular subtypes (luminal A, luminal B, triple-negative/basal-like, HER2-enriched, and normal-like breast cancer) is important in treatment strategy and hence their prognosis [2]. The survival rate improves with early diagnosis [3]. Numerous hazard factors such as family history, gene mutations, sex, aging, estrogen, and unhealthy lifestyle could increase BC probability [4]. The most BC widely recognized symptom is a new mass or lump [5] that has been diagnosed by many methods such as screening tests (physical tests and mammogram), lab tests (tumor markers as CEA and CA15.3), and breast biopsy [6]. However, these screening methods have limitations such as radiation exposure and maybe affected by breast density [7]. Moreover, no effective blood-based marker is
available for BC detection, particularly for patients with early-stage and low-grade tumor [7].

Epigenetic mutations, involved DNA methylation, were responsible for the control of gene expression by regulating gene transcription [8]. Most DNA methylation is catalyzed by DNA methyltransferases and exhibits essential physiological role in numerous key functions of cells [9]. Aberrant promoter methylation of numerous tumor suppressor genes was obtained in BC initiator lesions, representing that DNA methylation is an early event in breast carcinogenesis [10].

Among these tumor suppressor genes, tensin homolog (PTEN) gene and its function loss affects the increased levels of tumor aneuploidy that is one of the most projecting features of human cancers [11]. PTEN gene is reported to be mutated in a number of human malignancies including prostate [12], cervical [13], and BCs [14]. Former studies have shown an association of PTEN promoter methylation with its diminished expression in BC [15] which may indicate its role in breast carcinogenesis [16]. In a previous study [17], it was reported that transforming growth factor β (TGF-β) facilitates PTEN suppression in pancreatic cancer cell. Another tumor suppressor gene is SMAD4 which shows critical role in the TGF-β signaling pathway as well. TGF-β acts as significant characters in various biological procedures, such as apoptosis, in addition to cancer initiation and progression [18, 19]. Mutation and promoter hypermethylation of SMAD4 has been reported in numerous human cancers [20].

Thus, the two suppressor genes PTEN and SMAD4 are linked through TGF-β pathway as they can mediate carcinogenesis [21], and their loss may attributes to cancer aggressiveness [22]. Hence, this study aimed to investigate methylation patterns of both PTEN and SMAD4 among primary BC patients and compare their role with other non-cancer groups as well as assess their diagnostic effectiveness with other tumor markers (CEA and CA15.3). Also, we aimed to evaluate the association between these patterns and clinicopathological features.

Methods

Patients and specimen collection

A total of 110 patients were involved; they were enrolled from Surgical Department, Oncology Centre, Egypt. They were divided according to their clinical diagnosis into primary BC group (n = 80, 72.7%) and benign breast diseases (n = 30, 27.2%). BC patients fulfilled the inclusion criteria as being diagnosed with primary BC patients before receiving any treatment or underwent surgical resection and have not any other tumors. Demographic and clinico–pathological data for enrolled individuals were collected from their medical reports. BC patients were diagnosed according to their staging and grading systems following the TNM classification [23]. In addition, 30 healthy individuals were included and they served as control group. Blood samples (3 mL) were withdrawn from all participants in tubes EDTA and centrifuged at 4000 rpm for 5 min. at 4 °C for further processing to detect the investigated markers.

Hormonal receptor status analysis and molecular subtype of BC

For each sample, the expression of hormonal receptors and BC molecular subtype was identified by immunohistochemistry (IHC) method using formalin-fixed paraffin-embedded tissue. IHC staining was evaluated. Both ER and PgR were consider positive if ≥ 10% nuclei was positively stained using ten high-power field, and HER-2neu was considered positive if scored as + 3.

Tumor markers assessment

By enzyme-linked immunosorbent assay (ELISA), both CEA and CA15.3 were determined in serum samples using available commercial kits (Immuno-spectrapcorporation, the Netherlands) based on instructions in the manual manufacturer’s protocol. Their levels were detected using GloMax-Multi detection system (Promega, USA).

DNA extraction

DNA was extracted using QIAamp DNA Min kit (Qiagen, Hilden, Germany), according to the manufacturers’ recommendations, which based on spin column for DNA extraction method. The purity and the concentration of the extracted DNA were detected before further investigation using nanodrop spectrophotometer (Quawell, Q-500, Sibnser, USA) then stored at – 20 °C till further restriction digestion.

Detection of DNA methylation pattern

DNA methylation pattern was detected using EpiTect Methyl II quantitative polymerase chain reaction (qPCR) System (Qiagen, Germany). This technique is based on the detection of remaining input genome after digestion with a methylation-sensitive restriction enzyme. This technique requires 2 phases: phase I, digestion of DNA samples which was carried out following the manufacturer instruction of EpiTect Methyl II DNA Restriction Kit. Briefly, it was as follows: the input genomic DNA was aliquoted into four equal portions and subjected to four tubes mock (M0), methylation-sensitive (Ms), methylation-dependent (Md), and methylation-sensitive-dependent enzyme (Msd). All 4 reactions were incubated at 37 °C for 6 h then at 65 °C for 20 min using thermal cycler (SureCycler 8800, Agilent, Santa Clara, CA, USA). Then, phase II is as follows: qPCR for methylation status (using Max3005P QPCR system; Stratagene, Agilent Technologies, CA, USA), the enzyme reactions were
mixed directly with qPCR master mix (RT² qPCR SYBR Green/ROX Master Mix, Cat number 330520) and were dispensed into a PCR plate containing pre-aliquoted primer mixes (EpiTect Methyl II qPCR Primer Assay). Real-time PCR is carried out using specified cycling conditions, 95 °C for 10 min (1 cycle), then 99 °C for 30 s and 72 °C for 1 min (3 cycles), and finally 97 °C for 15 s and 72 °C for 1 min (40 cycles). Finally, the raw ΔCT values were pasted into the data analysis spreadsheet (EpiTect Methyl II PCR Array Microsoft Excel based data analysis template), which automatically calculates the relative amount of methylated and unmethylated DNA fractions.

Data analyses
Data were analyzed using SPSS (SPSS, Inc., Chicago, USA; version 20) and GraphPad prism (version 6). Significant difference between groups was determined using (ANOVA) for normally distributed values and Kruskal-Wallis for non-normal distributed variables and Fisher's LSD as post-hoc test and P value were two-tailed and considered significant if < 0.05. Receiver operating characteristic (ROC) curve was constructed among studied groups to identify the specificities and sensitivities for investigated genes. Person correlation coefficient (r) was utilized for determining the association between target gene methylation degree and other parameters.

Results
Patients characteristic
Patients demographic and clinicopathological data were summarized in Table 1. Both benign and healthy controls were age matched (P = 0.923) with BC patients. Most of BC patients (56.2%) and patients with benign breast disease (56.7%) were premenopausal. For benign breast lesion, they were pathologically divided into 12 with follicular hyperplasia, 10 with intraductal papillomatosis, and 8 with fibrocystic changes. According to

| Parameter                        | Breast cancer | Benign | Healthy | P value |
|----------------------------------|---------------|--------|---------|---------|
| Number                           | 80            | 30     | 20      | –       |
| Age (years, mean ± SD)           | 52.4 ± 9.1    | 52.0 ± 9.3 | 51.5 ± 8.9 | 0.923*  |
| Menopause, number (percentage)   |               |        |         |         |
| Post-menopausal                  | 35 (43.8%)    | 13 (43.3%) | 8 (40%)  | 0.955** |
| Pre-menopausal                   | 45 (56.2%)    | 17 (56.7%) | 12 (60%) |         |
| Tumor invasion number (percentage)|              |        |         |         |
| In situ                          | 32(40%)       | –      | –       | –       |
| Invasive                         | 48(60%)       | –      | –       | –       |
| Tumor depth (stage)              |               |        |         |         |
| Early (T ≤ 2)                    | 35(43.8%)     | –      | –       | –       |
| Late (T > 2)                     | 45 (56.2%)    | –      | –       | –       |
| Tumor grade                      |               |        |         |         |
| Low (G1)                         | 30(37.5%)     | –      | –       | –       |
| High (G2–3)                      | 50 (62.5%)    | –      | –       | –       |
| Lymph node invasion              |               |        |         |         |
| Negative                         | 42 (52.5%)    | –      | –       | –       |
| Positive                         | 38 (47.5%)    | –      | –       | –       |
| Estrogen receptor (ER)           |               |        |         |         |
| Negative                         | 40 (50%)      | –      | –       | –       |
| Positive                         | 40 (50%)      | –      | –       | –       |
| Progesterone receptor (PgR)      |               |        |         |         |
| Negative                         | 28 (35%)      | –      | –       | –       |
| Positive                         | 52 (65%)      | –      | –       | –       |
| HER-2/neu status                 |               |        |         |         |
| Negative                         | 28 (35%)      | –      | –       | –       |
| Positive                         | 52 (65%)      | –      | –       | –       |

*Statistical analysis was carried out by (a) ANOVA test and (b) chi-squared (χ²) test in case of dichotomized values
P > 0.05 is considered non-significant; P ≤ 0.05 is considered significant
the hormonal receptor status, BC patients were classified into luminal A (ER/PR+, HER2−; 8/80 (10%)), luminal B (ER/PR+, HER2+; 52/80 (65%)), and triple negative (ER−/PR−/HER2−; 20/80 (25%)).

DNA methylation status and tumor markers level among investigated groups
BC patients were associated with high methylation degree of PTEN and SMAD4. In contrast to CEA (Fig. 1a) and CA15.3 (Fig. 1b), BC patients were associated with high methylation degree of PTEN (77.1 ± 17.9 vs. 24.9 ± 4.5 for benign and 15.1 ± 1.4 for healthy individuals; Fig. 1c) and SMAD4 (70.1 ± 14.4 vs. 28.2 ± 0.61 for benign and 29.5 ± 3.6 for healthy individuals; Fig. 1d). To evaluate the diagnostic efficacy for investigated items, ROC curves (Fig. 2a–d) were plotted. Despite CEA (AUC = 0.538) and CA15.3 (AUC = 0.686), ROC curve analysis revealed that both PTEN (AUC = 0.992) and SMAD4 (AUC = 0.853) had extremely discriminative power for good differentiating BC from all non-cancer individuals (benign and healthy combined).

PTEN and SMAD4 high methylation pattern and clinicopathological features
No significant result was reported between methylation of PTEN and SMAD4 with either age or menopausal status as shown in Table 2. High PTEN methylation degree was significantly associated with tumor late stage (84.2 ± 17.4 vs. 67.4 ± 13.8), positive lymph node metastasis (84.2 ± 18.5 vs. 70.6 ± 14.8), positive ER (81.3 ± 19.7 vs. 70.6 ± 14.8), positive PR (79.5 ± 19.1 vs. 72.5 ± 14.7), and positive HER2 (80.7 ± 19.0 vs. 70.2 ± 13.5) as shown in Fig. 3a–f. Similarly, high SMAD4 methylation degree was significantly associated (P < 0.05) with high grade (74 ± 14.4 vs. 63.3 ± 12.01), tumor late stage (84.2 ± 17.4 vs. 64.5 ± 12.7), positive lymph node metastasis (75.1 ± 14.1 vs. 65.6 ± 13.4), positive ER (72 ± 15.5 vs. 68.2 ± 13.2), positive PR (72.8 ± 14.5 vs. 65.2 ± 13.3), and positive HER2 (72.3 ± 14.6 vs. 66 ± 13.4) as shown in Fig. 4a–f. Moreover, as shown in Table 2, both methylated PTEN and SMAD4 genes were significantly (P < 0.05) correlated with CA15.3, tumor stage, grade, and lymph node involvement. Moreover, PTEN methylation was significantly related with breast cancer subtypes. High significant correlation was detected between PTEN and SMAD4 methylation (r = 0.727, P = 0.0001).

Diagnostic performance of PTEN and SMAD4 methylation degree
As reported in Table 3, methylated PTEN and SMAD4 genes were superior to CEA and CA15.3 in early BC detection. Also, their diagnostic ability was better than other tumor marker in differentiated early stages and low-grade breast cancer; however, the sensitivity of CEA was more than that of SMAD4 in detection of low-grade tumors (Table 3).

![Fig. 1](image-url) The distribution of investigated markers among the investigated groups. a Level of CEA, (b) level of CA 15.3, (c) level of PTEN, and (d) level of SMAD4.
Fig. 2 Receiver operating characteristic curve for (a) CEA, (b) CA15.3, (c) methylated PTEN, and d methylated SMAD4 to distinguish patients with breast cancer from non-cancer (healthy and benign combined).

| Factors          | PTEN methylation status | SMAD4 methylation status |
|------------------|-------------------------|--------------------------|
|                  | $R$                     | $P$ value                | $R$                     | $P$ value                |
| Age              | $-0.09$                 | 0.315                    | $-0.017$                | 0.844                    |
| Menopause        | $-0.1$                  | 0.270                    | $-0.016$                | 0.861                    |
| CEA              | 0.209                   | 0.017                    | 0.086                   | 0.329                    |
| CA15-3           | 0.395                   | 0.0001                   | 0.265                   | 0.002                    |
| Tumor stage      | 0.507                   | 0.0001                   | 0.320                   | 0.004                    |
| Tumor grade      | 0.492                   | 0.0001                   | 0.329                   | 0.003                    |
| Lymph node       | 0.454                   | 0.0001                   | 0.323                   | 0.004                    |
| ER               | 0.203                   | 0.07                     | 0.120                   | 0.289                    |
| PgR              | 0.315                   | 0.004                    | 0.237                   | 0.034                    |
| HER2             | 0.042                   | 0.711                    | 0.194                   | 0.084                    |
| Molecular subtypes | 0.321                 | 0.0001                   | 0.154                   | 0.175                    |
| Methylated SMAD4 | 0.727                   | 0.0001                   |                          |                          |

*Correlations were determined according to Pearson coefficient; $P < 0.05$ was significant.
Discussion

BC is the most frequently occurring in women worldwide and the second most prevalent cancer [24]. Also, it is the most common tumor affecting Egyptian females [25]. Early-stage cancer detection may minimize death rates for BC. There are multiple diagnostic methods for breast tumor detection; however, because of the weakness of these approaches, researchers have used distinctive biomarkers as alternatives to detect BC [26]. Carcinogenesis arises from significant modifications in DNA methylation within the cell. These alterations are distinguished by the hypomethylation or hypermethylation of multiple 5′-cytosine-phosphate-guanine-3′ (CpG) islands [27]. So, the aim of this study was to evaluate whether the methylation pattern of both SMAD4 and PTEN genes was correlated with clinical variables of breast carcinoma.

Both SMAD4 and PTEN have been revealed a closely linked in the regulation of tumor infiltration and distant metastasis. For instance, there were findings suggest that the loss of Smad4 and PTEN may lead to more aggressive disease and poor prognosis in patients with colorectal adenocarcinoma compared to the loss of SMAD4 or PTEN alone [28], pancreatic cancer [29], lung cancer [30], and invasive intestinal-type gastric cancer [22]. PTEN is a tumor suppressor gene; promoter methylation of PTEN is implicated in various types of cancer including non-small-cell lung carcinoma [31], gastric [32], cervical cancer [13, 33], and endometrial carcinoma [34], including BC [14, 15, 35]. Promoter hypermethylation of the PTEN gene is a key event in the progression of BC [36]. In the current study, it was observed that there were no correlations between age of individuals and methylation degree of PTEN (P=0.315); this result was in harmony with the study by [16] Alam et al., and it was in dissimilarity with a study of Kazim et al. [37], who revealed a significant difference with north Indian breast cancer patient’s age. In study by Wu et al. [35], who used MSP technology, only a few of CpG islands in the promoter region of genes were stately. This study noticed that hypermethylation of PTEN was significantly associated with menopausal status (P = 0.027); this is in disagreement with current results that investigated non-significant difference with menopause status (P = 0.238); variability in results could be due to the size of study groups, as well as applied methodology. For example, Kazim et al. used another method (methylation-specific PCR) on another race (Asian populations) [37].

Methylated PTEN status reported a significant correlation with tumor markers, tumor stage, and tumor

Fig. 3 Distribution of PTEN methylation degree among breast cancer patients according to tumor (a) stages, (b) grades, (c) lymph node, (d) estrogen receptor, (e) progesterone receptor, and (f) HER2 statuses. Significant difference was determined using Student’s t test. P value < 0.05 was considered significant.
grade; also, there was a significant correlation between methylated PTEN and PR ($P=0.004$). This is in agreement with the study of Alam et al. [16], as there was significant correlation noticed among PTEN methylation and tumor grade and tumor stage. These findings were inconsistent with previously reported studies such as Yari [36] and Zhang et al. [14], as they indicated no association between methylated PTEN with other pathological characteristics of patients. This difference in results may be due to genetic predisposition. Further study is in progress to investigate the relation between PTEN and clinical characteristics on a large cohort of Egyptian patients. Breast cancer can be divided into four molecular subtypes that differ in their response as previously reported [2]. In the current study, a significant relation was reported between PTEN and molecular subtypes of breast cancer which reveal the impact for detection of methylation status for further treatment strategy [38].

SMAD4 is a tumor suppressor gene that regulates cell proliferation, distinction, and extracellular matrix production [39]. It has been reported that SMAD4 acts as a prognostic biomarker in various human malignancies such as colorectal carcinoma [40] and pancreatic carcinoma [41], but its role as a prognostic marker in breast carcinoma is still unclear [42]. Deckers et al. [43]

---

**Table 3** Overall sensitivity, specificity, PPV, NPV, and accuracy of investigated methylated genes and tumor markers

| Variables | Sen.% | Spe. % | PPV% | NPV% | Acc.% |
|-----------|-------|--------|------|------|-------|
| Early detection of breast cancer vs. all non-cancer | | | | | |
| CEA (ng/ml) | 70 | 40 | 65.1 | 45.5 | 58.5 |
| CA15.3 (ng/ml) | 75 | 48 | 69.8 | 54.5 | 64.6 |
| PTEN | 100 | 94 | 96.4 | 100 | 97.7 |
| SMAD4 | 100 | 100 | 100 | 100 | 100 |
| Early stage breast cancer vs. all non-cancer | | | | | |
| CEA (ng/ml) | 51.1 | 51.4 | 57.5 | 45 | 51.3 |
| CA15.3 (ng/ml) | 51.1 | 51.4 | 57.5 | 45 | 51.3 |
| PTEN | 84.4 | 51.4 | 69.1 | 72 | 70 |
| SMAD4 | 66.7 | 40 | 58.8 | 48.3 | 55 |
| Low-grade breast cancer vs. all non-cancer | | | | | |
| CEA (ng/ml) | 66 | 60 | 73 | 51.4 | 66 |
| CA15.3 (ng/ml) | 54 | 50 | 54 | 50 | 54 |
| PTEN | 80 | 70 | 80 | 70 | 80 |
| SMAD4 | 60 | 60 | 60 | 60 | 60 |
CAM suggested appropriate modifications and made corrections. SS is MMS designed the experiments and performed all the experiments. EAS and BC.

Abbreviations
BC: Breast cancer; PTEN: Phosphatase and tensin homolog; TGF-β: tumor suppressor genes related to certain pathways.

Conclusions
In conclusion, to our knowledge, this is the first study to focus on the diagnostic efficacy of the methylation pattern for both SMAD4 and PTEN in BC and to assess their correlation with each other as two important tumor suppressor genes related to TGF-β pathway [17, 22]. In this study, methylation of SMAD4 can distinguish breast cancer patients from healthy and benign individuals, where methylation degree of SMAD4 in breast cancer is higher than methylation in benign and healthy controls. Methylation SMAD4 pattern may be a good power for early detection of BC and even when considering the high-risk BC group. This in disagreement with several studies that revealed that hypermethylation was not found in colorectal malignancies and small intestinal neuroendocrine tumors [45–47], but our results were in agreement with study by Onwuegbusi et al. who reported that 70% of esophageal carcinoma cases were found to be hypermethylated at SMAD4 promoter [48].

Acknowledgements
The authors would like to thank the Surgery and Pathology Departments, Mansoura University, for providing the blood samples and their pathological reports for the enrolled individuals.

Authors’ contributions
MMS designed the experiments and performed all the experiments. EAS and CAM suggested appropriate modifications and made corrections. SS is responsible for the statistical analysis. AD and AA analyzed the pathological data. All authors read and approved the final manuscript.

Funding
No funding was obtained for this study.

Availability of data and materials
Data is not available due to (ethical/legal/commercial) restrictions. Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.

Declarations

Ethics approval and consent to participate
The study protocol was accepted by the Medical Ethical Committee - National Research Centre with the code of (ID: 15170). Informed written consents were obtained from all patients and controls.

Consent for publication
Not applicable.

Competing interests
The authors report no conflicts of interest in this work.

Author details
1Biochemistry Department, Genetic Engineering and Biotechnology Research Division, High Throughput Molecular and Genetic Laboratory, Center for Excellences for Advanced Sciences, National Research Centre, Dokki, Giza, Egypt. 2Chemistry Department, Faculty of Science, Damietta University, Damietta 34517, Egypt. 3Surgical Oncology Department, Mansoura Oncology Centre, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Received: 21 December 2020 Accepted: 26 March 2021

References
1. Salta S, Nunes SP, Sousa MF, Lopes P, Freitas M, Caldas M, Antunes L, Castro F, Antunes p et al (2018) A DNA methylation-based test for breast cancer detection in circulating cell-free DNA. J Clin Med 7(11):420. https://doi.org/10.3390/jcm7110420
2. Alkhoulably F (2020) Molecular classification of breast cancer: a retrospective cohort study. Ann Med Surg 49:44–48. https://doi.org/10.1016/j.amsu.2019.11.021
3. Mahvi DA, Liu R, Grinstaff MW, Colson YL, Raut CP (2018) Local cancer recurrence: the realities, challenges, and opportunities for new therapies. CA Cancer J Clin 68(6):486–505. https://doi.org/10.3322/caac.21498
4. Rodgers KM, Udesky JO, Rudel RA, Brody JG (2018) Environmental chemicals and breast cancer: an updated review of epidemiological literature informed by biological mechanisms. Environ Res 160:152–182. https://doi.org/10.1016/j.envres.2017.08.045
5. Breast Cancer Treatment (PDC) (2014) Archived from the original on 5 July 2014. Retrieved 29 June 2014.
6. Consorti V, Housami N, Ghirardi M, Ferrari A, Spoletini M, Bellarosa S, Remida G, Gasparotti C, Galligioni E, Ciatto S (2011) Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: interval breast cancers at 1 year follow-up. Eur J Cancer 47(7):1021–1026. https://doi.org/10.1016/j.ejca.2010.12.002
7. Attallah AM, El-Far M, Omran MW, Abdallah SO, El-Desouky MA, El-Dosoky L, Abdelrazek MA, Attallah AA, Elwesh MA et al (2014) Circulating levels and clinical implications of epithelial membrane antigen and cytokerin-1 in women with breast cancer: can their ratio improve the results? Tumour Biol 35(11):10737–10745. https://doi.org/10.1007/s13277-014-2375-1
8. Uramova S, Kubatka P, Dankova Z, Kapinova A, Zalokova B, Samec M, Zubor P, Zulli A, Valentova V, Kwon TK, Solar P, Kello M, Kajo K, Busselberg D, Pec M, Danko J (2018) Plant natural modulators in breast cancer prevention: status quo and future perspectives reinforced by predictive, preventive, and personalized medical approach. EPMA J 9(4):403–419. https://doi.org/10.1007/s13167-018-0154-6
9. Zeng Y, Chen T (2019) DNA methylation reprogramming during mammalian development. Genes 10:257
29. Liu J, Sato Y, Elshoff DA, Turner RR, Giuliano AE, Shamonki JM, Swellam et al. Journal of Genetic Engineering and Biotechnology

10. Van Hoese AQ, Sato Y, Elshoff DA, Turner RR, Giuliano AE, Shamonki JM, Swellam et al. Journal of Genetic Engineering and Biotechnology

11. Vidotto T, Tetzl DF, Squire JA (2018) Distinct subtypes of genomic PT EN deletion size influence the landscape of aneuploidy and outcome in prostate cancer. Mol Cytogenet 11:1. https://doi.org/10.1186/s13039-017-0349-y

12. Reid ACH, Attard G, Ambrossine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Mallett H et al (2010) Molecular characterization of ERG, ETV1 and PTEN gene loci identifies patients at lowand high risk of death from prostate cancer. Br J Cancer 102(4):678–684. https://doi.org/10.1038/bjc.2010.554

13. Rizvi MMA, Alis MA, Ali, Mehdli SJ, Batra S, Mandal AK (2011) Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J Cancer Res Clin Oncol 137(8):1255–1262. https://doi.org/10.1007/s00432-011-0994-6

14. Locke WJ, Guanzon D, Ma C, Liew Y, Duesing KR, Fung KY, Ross JP (2019) The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review. Sci Rep 6(1):32723. https://doi.org/10.1038/srep32723

15. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H (2014) Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol 2014

16. Liu J, Cho SN, Akkanti B, Jin N, Mao J, Long W, Chen T, Zhang Y, Tang X, Wistuba II, Creighton CJ, Kheradmand F, DeMayo FJ (2015) ErbB2 pathway activation upon Smad4 loss promotes lung tumor growth and metastasis. Cell Rep 10(9):1599–1613. https://doi.org/10.1016/j.celrep.2015.02.014

17. Xu YB, Yang G, Zhu L, Tang YL, Zhang C, Ju Z, Yang X, Teng Y (2016) Gastric Lgr5 (+) stem cells are the cellular origin of invasive intestinal-type gastric cancer in mice. Cell Res 26(7):838–849. https://doi.org/10.1038/cr.2016.47

18. Syta JC, Lee HY, Lee JI, Wang L, Issa JP et al (2002) Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8:1178–1184

19. Khan YY, Lee HS, Kim WH (2002) Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 82(5):285–291. https://doi.org/10.1038/la812000042

20. Yang HU, Liu SW, Wang Y, Tsang CK, Nang YS (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinicopathological data. BMC Cancer 6:121. https://doi.org/10.1186/1471-2407-6-212

21. Salvesen HB, MacDonald N, Ryan A, Jacobs IU, Lynch ED, Akslen LA, Das S (2001) PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91(1):22–26. https://doi.org/10.1002/1097-0215(20001001)91:1<22::AID-IJC1002>3.0.CO;2-S

22. Wu L, Shen Y, Peng X, Zhang S, Wang M, Xu G, Zheng X, Wang J, Lu C (2016) Aberrant promoter methylation of cancer-related genes in human breast cancer. Oncol Lett 12(6):5145–5155. https://doi.org/10.3892/ol.2016.5535

23. Yari K, Payandeh M, Rahimi Z (2015) Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran. Int Soc Oncol BioMarkers (ISOBM)

24. Kazem Z, Wahabi K, Perwez A, Lai P, Rizvi MA (2019) PTEN genetic and epigenetic alterations define distinct subgroups in North Indian breast cancer patients. Asian Pac J Cancer Prev 20(1):260–267. https://doi.org/10.3322/ncm3.2019.06.07

25. Wintzen R, Iacobuzio-Donahue C, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH (2000) Loss of expression of Dpc4 in pancreatic cancer patients. J Cancer Epidemiol:2014

26. sameer AS, Siddiqi MA (2011) SMAD4 promoter hypermethylation in Kashmiri colorectal cancer cases. Saudi J Gastroenterol 17(4):297. https://doi.org/10.1054/bjoc.2000.1387

27. Swellam et al. Journal of Genetic Engineering and Biotechnology (2021) 19:54

28. Xu X, Ehdaie B, Ohara N, Yoshino T, Deng CX (2010) Synergistic action of Smad4 and PTEN in suppressing pancreatic ductal adenocarcinoma formation in mice. Oncogene 29(5):674–686. https://doi.org/10.1038/onc.2009.375

29. Liu J, Cho SN, Akkanti B, Jin N, Mao J, Long W, Chen T, Zhang Y, Tang X, Wistuba II, Creighton CJ, Kheradmand F, DeMayo FJ (2015) ErbB2
promoter methylation in small intestinal neuroendocrine tumors: an in vivo and in vitro study. Epigenetics 9(7):987–997. https://doi.org/10.4161/epi.28936

48. Onwuegbusi BA, Aitchison A, Chin SF, Kranjac T, Mills I, Huang Y, Lao-Sirieix P, Caldas C, Fitzgerald RC (2006) Impaired transforming growth factor beta signalling in Barrett’s carcinogenesis due to frequent SMAD4 inactivation. Gut 55(6):764–774. https://doi.org/10.1136/gut.2005.076430

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.